Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Public Backs New Plans To Protect Children From Tobacco
New research shows that 70 per cent of adults in the UK back proposals to protect children from tobacco by putting it out of sight in shops and 76 per cent support abolishing cigarette vending machines according to Cancer Research UK today (Wednesday) - on the second anniversary of the smoking ban in England.
generic viagra online
Recent Studies And Surveys
New England Journal of Medicine: Medicare Part D Update - Lessons Learned And Unfinished Business - "Since 2006, more than 40 million elderly and disabled people have had the opportunity to enroll in a Medicare Part D prescription-drug plan, as established under the Medicare Modernization Act (MMA) of 2003." At that time, lawmakers focused on several features of the proposed legislation. "Issues that received particular scrutiny were the unprecedented way that the benefit would be delivered (exclusively through private plans) and its design, featuring an unusual gap in coverage (sometimes called the "doughnut hole")." Four years into the program, "the Obama administration and the Democratically controlled Congress have an opportunity to review the program and identify areas for improvement." This study, The Medicare Policy Project of the Henry J. Kaiser Family Foundation, returns to some of the key questions raised during the congressional debate and in the years that led up to the program"s start (Neuman and Cubanski, July 23). (Note: KHN is a program of the Kaiser Family Foundation.)
News of the day
New Indicators Will Help Drive Quality Improvement In The NHS, UK
A list of more than 200 indicators of high quality care in the NHS is being published for the first time to help clinicians drive up the quality of care they deliver to patients, the Department of Health and The NHS Information Centre announced today.
Endocrinology

PolyMedix Receives United States Patent For Angiogenesis Inhibitor Compounds

PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, announced that the United States Patent and Trademark Office issued a patent assigned to PolyMedix relating to angiogenesis inhibitors. The patent, number 7,553,876, entitled "Polycationic Compounds and Uses Thereof," relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis. Angiogenesis is a process involving the growth of new blood vessels. The abnormal growth of new blood vessels is associated with many diseases, including age-related macular degeneration (AMD), the most common form of blindness in the elderly, cancers, and inflammation. Inhibiting abnormal angiogenesis may be useful therapy for these conditions. Lucentis® and Macugen® are two products currently approved for treatment of AMD. PolyMedix"s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor). "This is an exciting accomplishment for PolyMedix. This patent represents the first allowance from our applications relating to angiogenesis inhibition, and another compelling example of the efficiency and capabilities of our drug discovery approach," commented Nicholas Landekic, President and Chief Executive Officer. PolyMedix, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009